Title : Vildagliptin: a novel oral therapy for type 2 diabetes mellitus.

Pub. Date : 2007 Jun

PMID : 17563048






4 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 SUMMARY: Vildagliptin is an agent in a new class of medications called dipeptidyl peptidase IV (DPP4) inhibitors. Vildagliptin dipeptidyl peptidase 4 Homo sapiens
2 SUMMARY: Vildagliptin is an agent in a new class of medications called dipeptidyl peptidase IV (DPP4) inhibitors. Vildagliptin dipeptidyl peptidase 4 Homo sapiens
3 By inhibiting DPP4, vildagliptin causes an increase in glucagon like peptide-1 (GLP-1), an intestinal hormone that aids in glucose homeostasis and insulin secretion. Vildagliptin dipeptidyl peptidase 4 Homo sapiens
4 Vildagliptin has a halflife of about 90 minutes; however, > or =50% of DPP4 inhibition continues for more than 10 hours, allowing for once- or twice-daily dosing. Vildagliptin dipeptidyl peptidase 4 Homo sapiens